Biotech entity
Center for Biologics Evaluation and Research is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 190-day window averages about 0.1 stories each week. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window.
Last mentioned: 2d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Center for Biologics Evaluation and Research is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 190-day window averages about 0.1 stories each week. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window. At 6, the average consequence score sits below the same-window beat average of 6.1. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Tracy Beth Hoeg appears in 2 tracked Biotech stories published from March 4, 2026 through September 9, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 660 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tracy Beth Hoeg. Shared-story counts are live from our verified record — not editorial picks.
HHS fills four senior FDA roles
The Department of Health and Human Services announced permanent directors for the FDA's drug, vaccine and biologics, and tobacco centers, along with a fourth senior position.
Hoeg departs CDER
Dr. Tracy Beth Hoeg said she was fired from the Center for Drug Evaluation and Research; Davis began serving in an acting role.
Davis returns to FDA
Michael Davis rejoined the agency as a deputy director after working at a nonprofit pursuing psychedelic drug development.
A former psychiatric drug regulator with psychedelic nonprofit experience now leads FDA's drug center as Trump and RFK push faster reviews. Biopharma teams should watch psilocybin, MDMA and LSD programs plus the new vaccines center director.
Source: whec.com · orlandosentinel.com
FDA Commissioner Marty Makary is reportedly attempting to hire Dr. Tracy Beth Hoeg to lead a new initiative focused on antidepressant safety. The move is tied to a proposed 'bold new warning' for SSRIs and SNRIs, potentially addressing persistent side effects that have long been a point of contention between regulators and the pharmaceutical industry.
Tracy Beth Hoeg is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
